Skip to main content

OS Therapies Inc

corporate_fare Company Profile

OS Therapies Inc

OSTX·NYSE·Life Sciences·CIK 0001795091

OS Therapies Inc is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for Osteosarcoma (OS) and other solid tumors. Its mission is to address the significant need for new treatments in cancers of the bone in children and young adults. Osteosarcoma is described as an extremely challenging and often aggressive cancer with particular treatment challenges due to its location, changing genotypes, and high metastasis rates. The company is seeking to develop treatments that prevent metastasis and the recurrence of metastases. Its lead core product candidate is OST-HER2 (also known as OST31-164), a cancer immunotherapy product candidate that produces a cellular immune response against the cancer antigen HER2. In 2021, the company opened a clinical study to produce data for the U.S. Food and Drug Administration (FDA) to evaluate the safety and efficacy of OST-HER2 in patients after resection of recurrent Osteosarcoma, which achieved full enrollment of 41 patients in October 2023. In the first quarter of 2025, the company announced that its Phase IIb clinical trial achieved its primary endpoint with statistical significance. In October 2025, it announced final two-year overall survival data from the Phase IIb trial, in which 75% (27 of 36 evaluable patients) of OST-HER2-treated patients achieved two-year overall survival from the most recent pulmonary resection, compared with 40% in historical control patients (p < 0.0001). OST-HER2 was observed to be well-tolerated in the study. In January 2026, the company announced positive immune biomarker data from the Phase IIb trial indicating that activation of immune blood biomarkers in the interferon gamma pathway correlated with, and was predictive of, overall survival, distinguishing long-term survivors (≥ two years) from short-term survivors (< one year). These biomarker findings are based on exploratory analyses and have not been validated as surrogate endpoints for clinical benefit.

OS Therapies Inc (NYSE:OSTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 1 item for OSTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-16, rated 9/10. Recent SEC coverage for OSTX spans 10-Q.

Recent high-impact activity:

  • OS Therapies Q3 10-Q: Going Concern on $431,816 Cash, $30.3M Nine-Month Loss

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$28.75M
Diluted EPS
-$0.98
Op. Cash Flow
-$14.24M
Free Cash Flow
-$14.7M
Operating Income
-$28.71M
Cash & Equivalents
$269.83K
Debt / Equity
0.00×
Shares Outstanding
37.11M sh
Source: 10-K · filed 2026-03-31 · accession 0001213900-26-036629

Short Interest & Short Volume

7.73 days to cover

FINRA reported short interest of 2,760,127 shares in OSTX as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 7.7 days to cover at its recent average daily volume. On November 20, 2026, 62.1% of OSTX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)2,760,127 shares as of October 30, 2026
Change vs prior period▼ 2.1%
Days to cover7.73 at avg daily volume of 357,247
Daily short volume (FINRA facilities)62.1% of 331,409 shares on November 20, 2026
5-day average short volume43.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

$0.803
52-week range · as of 2026-11-16 $0.5799 – $2.25
Market cap
$42M
Volume
489.7K (0.7× avg)
3-mo avg 657.5K
Live data · 2026-11-22 12:33 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed OSTX - Latest Insights

OSTX
Nov 16, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.653
Real-time Price: $0.803 info
Change: +$0.150 (+23%) info
Market Cap: $41.997M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets